Stock Track | Harrow Health Plunges 10.62% Post-Market on Q1 Revenue and Earnings Miss

Stock Track05-12

Harrow Health Inc's stock experienced a 24-hour plunge of 10.62% in post-market trading, reflecting a sharp sell-off following the release of its latest financial results.

The decline was driven by the company's disappointing first-quarter 2026 performance, where revenue fell significantly short of analyst expectations. Harrow reported revenue of $44.2 million, missing the consensus estimate of $52.4 million, partly due to a non-recurring $8 million gross-to-net adjustment related to new commercial coverage for its VEVYE product. Furthermore, the company's loss per share widened to $0.74, worse than the anticipated loss, and its gross margin contracted to 61% from 68% a year earlier.

Despite the quarterly setback, management reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million and projected an improvement in the second quarter. However, the immediate reaction from investors was negative, focusing on the earnings and revenue miss as well as the pressure on profitability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188601574?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 08:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188601574","market":"sg","top_or_hot":-1,"title":"Stock Track | Harrow Health Plunges 10.62% Post-Market on Q1 Revenue and Earnings Miss","media":"Stock Track","content":"<p>Harrow Health Inc's stock experienced a 24-hour plunge of 10.62% in post-market trading, reflecting a sharp sell-off following the release of its latest financial results.</p><p>The decline was driven by the company's disappointing first-quarter 2026 performance, where revenue fell significantly short of analyst expectations. Harrow reported revenue of $44.2 million, missing the consensus estimate of $52.4 million, partly due to a non-recurring $8 million gross-to-net adjustment related to new commercial coverage for its VEVYE product. Furthermore, the company's loss per share widened to $0.74, worse than the anticipated loss, and its gross margin contracted to 61% from 68% a year earlier.</p><p>Despite the quarterly setback, management reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million and projected an improvement in the second quarter. However, the immediate reaction from investors was negative, focusing on the earnings and revenue miss as well as the pressure on profitability.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Harrow Health Plunges 10.62% Post-Market on Q1 Revenue and Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Harrow Health Plunges 10.62% Post-Market on Q1 Revenue and Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-12 08:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Harrow Health Inc's stock experienced a 24-hour plunge of 10.62% in post-market trading, reflecting a sharp sell-off following the release of its latest financial results.</p><p>The decline was driven by the company's disappointing first-quarter 2026 performance, where revenue fell significantly short of analyst expectations. Harrow reported revenue of $44.2 million, missing the consensus estimate of $52.4 million, partly due to a non-recurring $8 million gross-to-net adjustment related to new commercial coverage for its VEVYE product. Furthermore, the company's loss per share widened to $0.74, worse than the anticipated loss, and its gross margin contracted to 61% from 68% a year earlier.</p><p>Despite the quarterly setback, management reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million and projected an improvement in the second quarter. However, the immediate reaction from investors was negative, focusing on the earnings and revenue miss as well as the pressure on profitability.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"","article_id":"1188601574","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188601574","pubTimestamp":1778546705,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Harrow Health Inc's stock experienced a 24-hour plunge of 10.62% in post-market trading, reflecting a sharp sell-off following the release of its latest financial results.The decline was driven by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc"},"translate_title":"个股追踪|哈罗健康Q1营收盈利不及盘后暴跌10.62%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1},"content_text":"Harrow Health Inc's stock experienced a 24-hour plunge of 10.62% in post-market trading, reflecting a sharp sell-off following the release of its latest financial results.The decline was driven by the company's disappointing first-quarter 2026 performance, where revenue fell significantly short of analyst expectations. Harrow reported revenue of $44.2 million, missing the consensus estimate of $52.4 million, partly due to a non-recurring $8 million gross-to-net adjustment related to new commercial coverage for its VEVYE product. Furthermore, the company's loss per share widened to $0.74, worse than the anticipated loss, and its gross margin contracted to 61% from 68% a year earlier.Despite the quarterly setback, management reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million and projected an improvement in the second quarter. However, the immediate reaction from investors was negative, focusing on the earnings and revenue miss as well as the pressure on profitability.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188601574","isCrawlerRequest":true}